Oxidative stress in developmental brain disorders

Advances in Experimental Medicine and Biology

Volumn 724, Issue , 2012, Pages 278-290

  Hayashi, Masaharu ^a   Miyata, Rie ^a   Tanuma, Naoyuki ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; ARGININE; NORPHENAZONE; 4 HYDROXY 2 OCTENAL; 4-HYDROXY-2-OCTENAL; 8-HYDROXY-2'-DEOXYGUANOSINE; ALDEHYDE; DEOXYGUANOSINE; DRUG DERIVATIVE;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; ATAXIA TELANGIECTASIA MUTATED GENE; BRAIN CALCIFICATION; BRAIN DISEASE; CEREBELLUM DEGENERATION; COCKAYNE SYNDROME; CS GENE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DNA DAMAGE; DOWN REGULATION; EXCISION REPAIR; GENE; HUMAN; HUNTER SYNDROME; IMMUNOREACTIVITY; LIPID PEROXIDATION; MELAS SYNDROME; MOLECULAR PATHOLOGY; MRE11 GENE; MUTATIONAL ANALYSIS; MYOCLONUS EPILEPSY; NERVE CELL NECROSIS; NEURONAL CEROID LIPOFUSCINOSIS; NEUROPATHOLOGY; NHLRC1 GENE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETT SYNDROME; SPINAL MUSCULAR ATROPHY; XERODERMA PIGMENTOSUM; XP GENE; ADOLESCENT; ADULT; AGE; BRAIN; CHILD; DEVELOPMENTAL DISORDER; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; URINE;

ATAXIA TELANGIECTASIA;

ADOLESCENT; ADULT; AGE FACTORS; ALDEHYDES; BRAIN; BRAIN DISEASES; CHILD; COCKAYNE SYNDROME; DEOXYGUANOSINE; DEVELOPMENTAL DISABILITIES; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; XERODERMA PIGMENTOSUM; YOUNG ADULT;

EID: 84859516931     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0653-2_21     Document Type: Article

References (57)

1. Hayashi M. Oxidative stress in developmental brain disorders. Neuropathology 2009; 29(l):l-8.
2. Willcox JK, Ash SL, Catignani GL. Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr2004; 44(4):275-295.
3. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathology Int 1999; 49(2):91-102.
4. Iwai S. Synthesis and thermodynamic studies of oligonucleotides containing the two isomers of thymidine glycol. Chemistry 2001; 7(20):4343-4351.
5. Hayashi M, Tanuma N, Miyata R. The involvement of oxidative stress in epilepsy. In: Kozyrev D, Slutsky V, eds. Handbook of Free Radicals: formation, types and effects. New York: Nova Science Publishers, 2010:305-318.
6. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease. J Alzheimers Dis 2009; 16(4):845-858.
7. Shiihara T, Kato M, Ichiyama T et al. Acute encephalopathy with refractory status epilepticus: bilateral mesial temporal and claustral lesions, associated with a peripheral marker of oxidative DNA damage. JNeurol Sci 2006; 250(1-2):159-161.
8. Tanuma N, Miyata R, Hayashi M et al. Oxidative stress as a biomarker of respiratory disturbance in patients with severe motor and intellectual disabilities. Brain Dev 2008; 30(6):402-409.
9. Tanuma N, Miyata R, Kumada S et al. The axonal damage marker tau protein in the cerebrospinal fluid is increased in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. Brain Dev 2010; 32(6):435-439.
10. Izuta H, MatsunagaN, Shimazawa M et al. Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress and VEGF in vitreous body. Mol Vis 2010; 16:130-136.
11. Hayashi M, Arai N, Satoh J et al. Neurodegenerative mechanisms in subacute sclerosing panencephalitis. JChildNeurol2002; 17(10):725-730.
12. Martin LJ. DNA damage and repair: relevance to mechanisms of neurodegeneration. J Neuropathol Exp Neurol 2008; 67(5):377-387.
13. Kraemer KH, Patronas NJ, Schiffmann Ret al. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a comple genotype-phenotype relationship. Neuroscience 2007; 145(4):1388-1396.
14. Hayashi M. Role of oxidative stress in xeroderma pigmentosum. Adv Exp Med Biol 2008; 637:120-127.
15. Hayashi M, Hayakawa K, Suzuki F et al. A neuropathological study of early onset Cockayne syndrome with chromosomal anomaly 47XXX. Brain Dev 1992; 14(1):63-67.
16. Hayashi M, Itoh M, Araki S et al. Oxidative stress and disturbed glutamate transport in hereditary nucleotide repair disorders. J Neuropathol Exp Neurol 2001; 60(4):350-356.
17. Saito Y, Shibuya M, Hayashi M et al. Cerebellopontine calcification: a new entitiy of idiopathic intracranial calcification? Acta Neuropathol 2005; 110(1):77-83.
18. Mody N, Parhami F, Sarafian TA et al. Oxidative stress modulates osteoblastic differentiation of vascular andbone cells. Free Radic Biol Med 2001; 31(4):509-519.
19. Massy ZA, Maziere C, Kamel S et al. Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. Pediatr Nephrol 2005; 20(3):380-382.
20. Hayashi M, Araki S, Kohyama J et al. Oxidative nucleotide damage and superoxide dismutase expression in the brains of xeroderma pigmentosum group A and Cockayne syndrome. Brain Dev 2005; 27(1):34-38.
21. Ahmad S I (edt). Molecular Mechanisms of Ataxia telangiectasia, Landes Bioscience Publication, 2006.
22. Takao N, Li Y, Yamamoto K. Protective roles for ATM in cellular response to oxidative stress. FEBS Lett 2000;472(1):133-136.
23. Stern N, Hochman A, Zemach N et al. Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of Atm-deficient mice. J Biol Chem 2002; 277(1):602-608.
24. Chen P, Peng C, Luff J et al. Oxidative stress is responsible for deficient survival and dendritogenesis in Purkinje neurons from ataxiatelangiectasia mutated mice. J Neurosci 2003; 23(36):11453-11460.
25. Russo I, Cosentino C, Del Giudice E et al. In ataxia-teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol 2009; 16(6):755-759.
26. Taylor AM, Groom A, Byrd PJ. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis. DNA Repair 2004; 3(8-9):1219-1225.
27. IijimaK, OharaM, SekiRetal. Dancing on damaged chromatin: functions of ATM and the RAD50/MRE11/NBS1 complex in cellular responses to DNA damage. J Radiat Res 2008; 49(5):451-464.
28. Oba D, Hayashi M, Minamitani M et al. Autopsic study of cerebellar degeneration in siblings with ataxia-telangiectasia-like disorder (ATLD). Acta Neuropathol 2010; 119(4):513-520.
29. Kohlschutter A, Schulz A. Towards understanding the neuronal ceroid lipofuscinoses. Brain Dev 2009; 31(7):499-502.
30. Hachiya Y, Hayashi M, Kumada S et al. Mechanisms of neurodegeneration in neuronal ceroid-lipofuscinosis. ActaNeuropathol 2006; 111(2):168-177.
31. Anzai Y, Hayashi M, Fueki N et al. Protractedjuvenile neuronal ceroid lipofuscinosis-an autopsy report and immunohistochemical analysis. Brain Dev 2006; 28(6):462-465.
32. Bunge S, Knigge A, Steglich C et al. Mucopolysaccharidosis type IIIB (Sanfilippo B): identification of 18 novel alpha-N-acetylglucosaminidase gene mutations. J Med Genet 1999; 36(1):28-31.
33. Villani GR, Gargiulo N, Faraonio R et al. Cytokines, neurotrophins and oxidative stress in brain disease frommucopolysaccharidosis IIIB. JNeurosci 2007; 85(3):612-622.
34. Ohmi K, Greenberg DS, Rajavel KS et al. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 2003; 100(4):1902-1907.
35. Wraith JE, Scarpa M, Beck M et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167(3):267-277.
36. Matalon R, Kaul R, Michals K. Mucopolysaccharidosis and mucolipidosis. In: Duckett S, ed. Pediatric Neuropathology. Baltimore: Williams andWilkins, 1995:525-544.
37. Hamano K, Hayashi M, Shioda K et al. Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis ofhuman brain tissue. Acta Neuropathol 2008; 115(5):547-559.
38. Iizuka T, Sakai F. Pathogenesis of stroke-like episodes in MELAS: analysis of neurovascular cellular mechanisms. Curr Neurovasc Res 2005; 2(1):29-45.
39. Koga Y, Povalko N, Nishioka J et al. MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann NY Acad Sci 2010; 1201:104-110.
40. TrushimaE, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007; 145(4):1233-1248.
41. Katayama Y, Maeda K, Iizuka T et al. Accumulation of oxidative stress around the stroke-like lesions of MELAS patients. Mitochondrion 2009; 9(5):306-313.
42. Mizuguchi M, Hayashi M, Nakano I et al. Concentric structure of thalamic lesions in acute necrotizing encephalopathy. Neuroradiology 2002; 44(6):489-493.
43. HalliwellB.Oxidativestressandneurodegeneration:wherearewenow? JNeurochem2006;97(6):1634-1658.
44. Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy: from gene to therapy. Semin Pediatr Neurol 2006; 13(2):121-131.
45. Hayashi M, Araki S, Arai N et al. Oxidative stress and disturbed glutamate transport in spinal muscular atrophy. Brain Dev 2002; 24(8):770-775.
46. Araki S, Hayashi M, Tamagawa K et al. Neuropathological analysis in spinal muscular atrophy type II. ActaNeuropathol 2003; 106(5):441-448.
47. Hayashi M, Kumada S, Shioda K et al. Neuropathological analysis of the brainstem and cerebral cortex lesions on epileptogenesis in hereditary dentatorubral-pallidoluysian atrophy. Brain Dev 2007; 29(9):473-481.
48. Yamada M. CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol2008; 115(1):71-86.
49. Miyata R, Hayashi M, TanumaNetal. Oxidative stress in neurodegeneration in dentatorubral-pallidoluysian atrophy.JNeurol Sci 2008; 264(1-2):133-139.
50. Puranam KL, Wu G, Strittmatter WJ et al. Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria. Biochem Biophys Res Commun2006; 341(2):607-613.
51. Ganesh S, Puri R, Singh S et al. Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J Hum Genet 2006; 51(1):1-8.
52. Singh S, Suzuki T, Uchiyama A et al. Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population. J Hum Genet 2005; 50(7):347-352.
53. Gonzales ML, LaSalle JM. The role of MeCP2 in brain development and neurodevelopmental disorders. Curr Psychiatry Rep 2010; 12(2):127-134.
54. Armstrong DD. Neuropathology ofRett syndrome. J Child Neurol 2005; 20(9):747-753.
55. Pardo CA, Eberhart CG. The neurobiology ofautism. Brain Pathol 2007; 17(4):434-447.
56. Sierra C, Vilaseca MA, Brandi N et al. Oxidative stress in Rett syndrome. Brain Dev 2001; 23(Suppl 1):S236-S239.
57. De Felice C, Ciccoli L, Leoncini S et al. Systemic oxidative stress in classic Rett syndrome. Free Radic Biol Med 2009; 47(4):440-448.